Natera reports Q3 EPS (95c), consensus (96c)

Reports Q3 revenue $268.3M, consensus $259.25M. The company said, “We delivered robust volume and revenue growth in the third quarter, while demonstrating operational discipline with a significant reduction in cash burn. We continued to deliver on our strategic clinical roadmap with the publication of the landmark RenaCARE study in chronic kidney disease and key Signatera evidence across multiple cancer indications. As reflected in our revised guidance for the remainder of the year, we’ve increased our revenue target while reducing our cash burn goal, so we are well-positioned to help more patients than ever before.” As of September 30, 2023, Natera held approximately $936.6M in cash, cash equivalents, short-term investments and restricted cash, compared to $898.4M as of December 31, 2022.